Market Research Logo

Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015

Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Review, H2 2015’, provides an overview of the Pituitary ACTH Hypersecretion (Cushing's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pituitary ACTH Hypersecretion (Cushing's Disease) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing's Disease)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Pituitary ACTH Hypersecretion (Cushing's Disease) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Pituitary ACTH Hypersecretion (Cushing's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing's Disease)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing's Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Pituitary ACTH Hypersecretion (Cushing's Disease) Overview
Therapeutics Development
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Overview
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Development by Companies
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics under Investigation by Universities/Institutes
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Development by Companies
Pituitary ACTH Hypersecretion (Cushing's Disease) - Products under Investigation by Universities/Institutes
Pituitary ACTH Hypersecretion (Cushing's Disease) - Companies Involved in Therapeutics Development
Alder Biopharmaceuticals Inc.
Corcept Therapeutics Incorporated
Cortendo AB
Cyclacel Pharmaceuticals, Inc.
ElexoPharm GmbH
Ipsen S.A.
Isis Pharmaceuticals, Inc.
Novartis AG
Orphagen Pharmaceuticals, Inc.
Pfizer Inc.
Pituitary ACTH Hypersecretion (Cushing's Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALD-1613 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AT-814 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATR-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIM-23A758 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COR-005 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CORT-125134 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-GCCRRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketoconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MPP-482 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
osilodrostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pasireotide LAR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Antagonize ACTH Receptor for Cushing's Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pituitary ACTH Hypersecretion (Cushing's Disease) - Recent Pipeline Updates
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects
Pituitary ACTH Hypersecretion (Cushing's Disease) - Product Development Milestones
Featured News & Press Releases
Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Jun 10, 2015: Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
May 14, 2015: Corcept Therapeutics Announces Poster Presentations on Mifepristone for the Treatment of Patients With Cushing's Syndrome at the 27th Annual American Association of Clinical Endocrinologists
Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting
Jun 19, 2014: New Research on Corcept's Korlym for Patients with Cushing's Syndrome to be Presented at ICE/ENDO 2014
Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing’s Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease), H2 2015
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Alder Biopharmaceuticals Inc., H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Cortendo AB, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by ElexoPharm GmbH, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Ipsen S.A., H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Novartis AG, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Pipeline by Pfizer Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) Therapeutics - Recent Pipeline Updates, H2 2015
Pituitary ACTH Hypersecretion (Cushing's Disease) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease), H2 2015
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing's Disease) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report